RTI uses cookies to offer you the best experience online. By and clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Accept
  • Home
  • Impact
  • Publications
  • Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder

Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder

Aldridge, A., Kroutil, L., Cowell, A., Reeves, D., & Van Brunt, D. (2011). Direct costs to private insurers of diversion of medications for attention-deficit/hyperactivity disorder. PharmacoEconomics, 29(7)(1170-7690), 621 - 635.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Presidential youth fitness program implementation
Article

Missense and truncating variants in CHD5 in a dominant neurodevelopmental disorder with intellectual disability, behavioral disturbances, and epilepsy
Article

Trends in place of early-season influenza vaccination among adults, 2014-15 through 2018-19 influenza seasons-The importance of medical and nonmedical settings for vaccination
Article

Correction to